Drug Profile
Research programme: autoimmune therapeutics - Scripps Research Institute
Alternative Names: SR 1001Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Scripps Clinic
- Class Small molecules
- Mechanism of Action Retinoic acid receptor alpha antagonists; Retinoic acid receptor gamma antagonists; Th17 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
- 18 Apr 2011 Research programme: autoimmune therapeutics - Scripps Research Institute is available for licensing. http://www.scripps.edu
- 18 Apr 2011 Preclinical trials in Multiple sclerosis in USA (unspecified route)